Prevention and management of urinary tract infections following endoscopic and urological surgery using one dose daily of tobramycin.
The therapeutic activity of a single dose of 150 mg of tobramycin, parenteral administration, was studied in the prophylaxis of urinary tract infection (UTI) postoperative or postendoscopic. This study incorporated 85 patients of both sexes ranging in age from 18-91 years; 20 had had previous UTI. Duration of therapy ranged from 5 to 15 days and was determined by clinical response; 70 of 85 patients clinically observed achieved excellent results, 10 good and 5 moderate. In 5 cases persistent asymptomatic bacteriuria recurred, indicating incomplete eradication of the microorganism. Results of data showed the clinical efficacy, safety and tolerance of tobramycin, in one dose only, in the prophylaxis of UTI posturological surgery, as well as its easy administration and limited cost.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D014031:Tobramycin / Q000008:administration & dosage* / Q000627:therapeutic use; D014551:Urinary Tract / Q000601:surgery*; D014552:Urinary Tract Infections / Q000517:prevention & control*
D014031:Tobramycin